

Name of the Issue:		DR. LAL PATHLABS LIMITED	
1	Type of Issue (IPO/FPO)	IPO	
2	Issue Size (Rs. Cr)	631.91*	
*Source: Final Post Issue Monitoring Report			
3	Grade of Issue alongwith name of the rating agency		
	Name	NA	
	Grade	NA	
4	Subscription Level (Number of times)	33.41*	
*Source: Final Post Issue Monitoring Report			
The above figure is net of cheque returns, withdrawals and technical/ multiple rejections			
5	QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges		
	Particulars	%	
	(i) Allotment in the Issue ⁽¹⁾	2.81%	29.27%
	(ii) at the end of the 1st Quarter immediately after the listing of the Issue (Dec 31, 2015)	10.14%	
	(iii) at the end of 1st FY (March 31, 2016)	12.28%	
	(iv) at the end of 2nd FY (March 31, 2017)	16.42%	
	(v) at the end of 3rd FY (March 31, 2018)*	NA	
* QIB Holding not disclosed as reporting for relevant fiscal years has not been completed			
Source: (1) Basis of Allotment (excludes pre-issue holding of QIBs), Stock Exchanges			
6	Financials of the Issuer		
	Parameters	1st FY (March 31, 2016)	2nd FY (March 31, 2017)
			3rd FY (March 31, 2018)
			(Rs. Crore)
	Income from operations	765.40	881.87
	Net Profit for the period	125.75	147.21
	Paid-up equity share capital	82.68	83.07
	Reserves excluding revaluation reserves	395.84	541.9
			707.8
7	Trading Status in the scrip of the Issuer		
	Company's Equity Shares are listed on both the BSE Limited and the National Stock Exchange of India Limited		
	The Shares have not been suspended or delisted		
	Particulars	Status	
	(i) at the end of 1st FY (March 31, 2016)	Frequently Traded	
	(ii) at the end of 2nd FY (March 31, 2017)	Frequently Traded	
	(iii) at the end of 3rd FY (March 31, 2018)	Frequently Traded	
8	Change in Directors of Issuer from the disclosures in the offer document		
	Particulars	Name of the Director	Appointed / Resigned
	(i) at the end of 1st FY (March 31, 2016)	Nil	Nil
	(ii) at the end of 2nd FY (March 31, 2017)	Naveen Wadhwa	Resigned
	(i) at the end of 2nd FY (March 31, 2017)	Sandeep Singhal	Resigned
	(ii) at the end of 2nd FY (March 31, 2017)	Dr. Murugan Pandian	Resigned
	(iii) at the end of 3rd FY (March 31, 2018)	Nil	Nil
9	Status of implementation of project/ commencement of commercial production		
	(i) Details of Estimated Schedule of Implementation of Projects forming part of the Objects of the Issue as per Prospectus		
	Not Applicable		
	(ii) Actual implementation		
	Not Applicable		
	(iii) Reasons for delay in implementation, if any		
	Not Applicable		
10	Status of utilization of Issue proceeds		
	As the Offer is an offer for sale and our Company will not receive any proceeds from the Offer and the entire amount after deduction of Offer expenses will be remitted to the Selling Share		
11	Comments of monitoring agency, if applicable	Not Applicable	

12 Pricing Data

Issue Price (Rs.)	550
retail discount (Rs.)	15
Designated Stock Exchange	NSE
Listing Date:	December 23, 2015

Price parameters	At close of listing day - December 23, 2015	At close of 30th calendar day from listing day - Jan 21, 2016 ⁽¹⁾	At close of 90th calendar day from listing day - Mar 21, 2016 ⁽²⁾	As at the end of 1st FY after the listing of the issue (March 31, 2016)			As at the end of 2nd FY after the listing of the issue (March 31, 2017)			As at the end of 3rd FY after the listing of the issue (March 31, 2018)		
				Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (NSE)	825.00	728.95	918.25	923.30	966.90	696.50	967.55	1,280.00	770.00	876.3	976.3	737.35
CXN NIFTY	7,865.95	7,276.80	7,704.25	7,738.40	7,034.20	6,825.80	9,173.80	9,218.40	7,516.85	10,113.7	11,130.4	9,103.5

Note:

(1) 30th calendar day has been taken as listing date plus 29 calendar days

(2) 90th calendar day has been taken as listing date plus 89 calendar days

No sectoral index has been considered

Source: NSE

13 Basis for Issue Price

Peer Group: There is no listed company in India engaged in the same line of business. Hence, it is not possible to provide an industry comparison in relation to the Company

Accounting ratio	As disclosed in the offer document*	At the end of 1st FY (March 31, 2016)	At the end of 2nd FY (March 31, 2017)	At the end of 3rd FY (March 31, 2018)
EPS (Basic)	DR. LAL PATHLABS LIMITED #####	15.31	17.77	20.85
P/E	DR. LAL PATHLABS LIMITED 35.78	60.31	51.96	42.03
RoNW (%)	DR. LAL PATHLABS LIMITED 27.56	26.3%	23.55%	21.72%
NAV per share	DR. LAL PATHLABS LIMITED 53.56	57.88	75.23	94.97

* Sourced from Prospectus dated December 16, 2015. Disclosure is based on standalone financial information disclosed in the Prospectus

Key ratios for the company have been calculated as follows

(i) EPS - basic reported as in company filings

(ii) P/E is calculated as Offer price/ EPS (Basic) or the market price as at the end of the year / EPS (Basic).

(iii) Return on Net Worth has been computed as Net Profit after tax (as restated) divided by Net Worth at the end of the Fiscal Year

(iv) Net Asset Value per Equity Share has been computed as net worth divided by total number of equity shares outstanding at the end of the Fiscal Year

14 Any other material information

Information	Date
Dr. Lal PathLabs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 27, 2016, approved: 1. Acquisition of M/s. Delta Ria and Pathology Private Limited ("DRPPL"); 2. Acquisition of additional 10% stake in M/s. Paliwal Diagnostics Private Limited ("PDPL") and Paliwal Medicare Private Limited ("PMPL").	27-May-16
Dr. Lal PathLabs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 27, 2016 approved shifting of the Registered Office of the Company from 54, Hanuman Road, New Delhi - 110001 to "E-2 Block, Sector 18, Rohini, New Delhi 110089" w.e.f. May 27, 2016.	27-May-16
With reference to increase in Volume, Dr. Lal PathLabs Ltd has submitted to BSE a copy of Clarification	31-Aug-16
Dr. Lal PathLabs Ltd has informed BSE that the Board of Directors in their meeting held on February 02, 2017 have recommended the appointment of M/s. Deloitte Haskins & Sells LLP as Statutory Auditors of the Company, for a period of five years, in place of the existing auditors M/s. S. R. Batliboi & Co., Chartered Accountants, in compliance with the mandatory rotation of auditors as per the provisions of the Companies Act, 2013	2-Feb-17
In compliance with Regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (LODR Regulations), we wish to inform you that the Board of Directors in their meeting held today,	12-May-17
Board approved, acquisition of Dr. Lal Path Labs Bangladesh Pvt. Ltd. in Bangladesh.	7-Aug-17

For further information, please refer to www.bseindia.com and www.nseindia.com